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Abstract: 
Purpose: It is not known if changes in arterial wall inflammation associate with 
subsequent changes in the rate of structural progression of atherosclerosis. 
Methods: In this  sub-study of the dal-PLAQUE clinical trial, multi-modal imaging was 
performed using 18-Fludeoxyglucose (FDG) positron emission tomography (PET, at 0 and 
6 months) and magnetic resonance imaging (MRI, at 0 and 24 months). The primary 
objective was to determine whether increasing FDG uptake at 6-months predicted 
atherosclerosis progression on MRI at 2 years. Arterial inflammation was measured by the 
carotid FDG target to background ratio (TBR), and atherosclerotic plaque progression was 
defined as the percent change in carotid mean wall area (MWA) and mean wall thickness 
(MWT) on MRI between baseline and 24 months.  
Results: The mean age of the population was 62.5 years, and 12 (28.6 %) were female. In 
participants with (vs. without) any increase in arterial inflammation over 6 months, both 
the long-term changes in MWT (% change MWT: 17.49% vs. 1.74%, p=0.038) and MWA (% 
change MWA: 25.50% vs. 3.59%, p = 0.027) were significantly greater. Results remained 
significant after adjusting for clinical and biochemical covariates. Individuals with no 
increase in arterial inflammation over 6 months had no significant structural progression 
of atherosclerosis over 24 months, as measured by MWT (p=0.616) or MWA (p=0.373).  
Conclusions: Short-term changes in arterial inflammation are associated with long-term 
structural atherosclerosis progression. These data support the concept that therapies that  
reduce arterial inflammation may attenuate or halt progression of atherosclerosis. 
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1 Introduction: 
Atherosclerosis and its major clinical consequences, myocardial infarction and stroke, are 
leading causes of mortality and morbidity worldwide. Inflammation plays a crucial role in 
the development and progression of atherosclerosis, and can be non-invasively measured 
using 18-Fludeoxyglucose (FDG) positron emission tomography/computed tomography 
(PET/CT).1, 2  FDG is a glucose analog that is retained within cells at a rate proportional to 
glucose dependent metabolism; and compared to other vascular cells, FDG uptake is avid in 
immune cells. In the vascular wall, this correlates strongly with atherosclerotic plaque 
burden, and macrophage infiltration.3 Rapid changes in FDG arterial uptake have been 
observed in humans in response to therapeutic interventions. However, there is limited 
data examining how these short-term changes in inflammatory activity in an arterial wall 
relate to subsequent atherosclerosis progession. 
The dal-PLAQUE study was a phase 2b double blind, randomized, placebo-
controlled trial examining the effects of the cholesterol-ester-transfer-protein (CETP) 
modulator dalcetrapib on structural and inflammatory characteristics of arterial wall 
atherosclerosis by PET/CT over a 6 month period, and/or by magnetic resonance imaging 
[MRI] imaging over 24-months.4 Prior analysis of dal-PLAQUE identified a significant 
association between changes in carotid arterial inflammation over 6 months and 
enlargement of the total vessel area at 24 months. However, the total vessel area includes 
not only arterial wall, but also the lumen, and this observation could have simply reflected 
changes in the lumen, thus making it difficult to conclude whether these early 
inflammatory changes predicted atherosclerosis development. Indeed, there is limited data 
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in humans examining the relationship between changes in arterial inflammation and 
atherosclerotic disease progression. Further, while dal-PLAQUE included an intervention 
(which did not significantly change arterial inflammation), it provides an opportunity to 
test the hypothesis that changes in arterial inflammation over time (regardless of the 
underlying treatment milieu) result in changes in plaque progression. Accordingly, the 
objective of this study is to determine whether short-term changes in arterial inflammation 
(measured by FDG-PET) predicted long-term changes atherosclerosis progression 
(measured as wall thickness and wall area by MRI).   
2 Methods: 
2.1 Study design 
This was a prospective, sub-study of participants enrolled in the dal-PLAQUE clinical trial. 
The design of dal-PLAQUE has been described in detail in previous publications.4, 5 Briefly, 
dal-PLAQUE enrolled 130 participants from 11 centers in the United States and Canada. 
Participants were randomized (1:1) to receive either dalcetrapib 600 mg/day or placebo 
over a 24-month period. Participants could undergo 18-FDG-PET/CT to evaluate 
inflammation in the carotid arteries at 3 and 6 months; and/or black-blood MRI to assess 
anatomic indices of carotid plaque burden at 6-, 12- and 24-months (undergoing all 
imaging time points was not required). This analysis included 42 participants from dal-
PLAQUE who had serial FDG-PET/CTs at baseline and 6 months, and serial MRIs at baseline 
and two years. The study was approved by each participating center’s institutional review 
committee, and all subjects provided informed consent.  
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2.2 Imaging by PET/CT 
Imaging protocols for FDG-PET/CT have been described in detail in previous publications.4, 
5 FDG-PET/CT imaging of the carotid arteries was performed using previously validated, 
reproducible imaging methods.6, 7 Maximum standard uptake values (SUV) of FDG were 
measured, in axial orientation, along each carotid artery from 1 cm above to 2 cm below the 
bifurcation by manually drawing circular regions of interest that encompassed the vessel 
wall at 3-5 mm increments. Target-to-background ratios (TBR) were calculated for each 
segment by dividing each SUV value by the background venous FDG activity measured in 
the internal jugular veins. The TBR of the most diseased segment (MDS) was calculated as a 
mean of the three contiguous segments centered at the vessel segment with the highest 
maximum TBR, and was used as the primary measure of FDG uptake for this study. 
2.3 Imaging by MRI 
MRI imaging of the common carotid arteries was performed using previously validated 
methods, which included proton density-weighted, T1-weighted and T2-weighted dark-
blood turbo spin echo sequences to image the vessel walls, with additional phase contrast 
and time-of-flight sequences for better localization of carotid bifurcations.8, 9 External and 
internal walls of the carotid arteries were manually traced, and vessel wall area and 
thickness were calculated as the primary markers of atherosclerosis burden for this 
analysis. 
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2.4 Statistical analysis 
The primary independent variable of interest was an increase in carotid arterial 
inflammation (i.e. increase in TBR) between baseline and 6-months. Percent changes in 
mean wall thickness (MWT) and mean wall area (MWA) of the carotid arteries were 
calculated by MRI between baseline and 24 months as the primary outcomes of interest.  
The primary analysis compared whether increase FDG activity at 6 months was 
associated with significant difference in percent change in MWT by MRI at 24 months using 
linear regression. Further multivariable linear regression analyses were performed to 
assess whether these differences remained significant after adjusting for 1) demographic 
variables and 2) selected baseline clinical, biochemical or imaging variables. Potential 
covariates were selected based on their established relationship with atherosclerosis 
development in prior literature, and included demographic variables (e.g. age, sex), 
cardiovascular risk factors, history of coronary artery disease, and biochemical markers of 
inflammation (e.g. C-reactive protein (CRP), Interleukin-6 (IL-6) and plasminogen activator 
inhibitor-1 (PAI-1) activity). Of these inflammatory biomarkers, PAI-1 activity was 
previously shown to predict changes in MWA on MRI in a prior dal-PLAQUE analysis.10 
Covariates significantly associated with MWT at 24 months on univariate analysis (at a 
threshold p-value of 0.05) were carried forward in the multivariable analysis. Similar 
analyses were performed using the outcome of percent change in MWA measured by MRI 
at 24 months. Sensitivity analyses were also performed using absolute changes in MWA 
and MWT. 
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Several exploratory analyses were also performed. To account for changes in the 
PET signal that could be attributable to differences in arterial wall area, we further 
adjusted for mean wall area at 6 months in our multivariable analysis. We also examined 
whether increased FDG activity remained a significant predictor of plaque progression by 
MRI after adjusting for biochemical markers of inflammatory activity, measured by C-
reactive protein between baseline and 12 months. Also, in a subset of participants with 
FDG-PET imaging at 3 months, we examined whether arterial inflammation was associated 
with atherosclerotic progression by MRI at 2 years, and the correlation between the 
percent change in SUV activity from baseline to 3- and 6-months. The association between 
changes in arterial inflammation and atherosclerosis progression, both measured between 
baseline and 6-months, was also examined. The association between baseline arterial 
inflammation and change atherosclerosis progression on MRI at 24 months was also 
measured. In participants with the largest amount of atherosclerosis progression on MRI 
(defined as the highest tertile group) we examined whether there was evidence of greater 
changes in arterial inflammation compared to groups with less atherosclerosis progression 
(defined as the lowest and middle tertile). Finally, to examine to short-term structural 
changes impact long-term atherosclerosis progression, we compared changes in MWT (and 
MWA) on MRI at 6 months and 24 months. Analyses were performed using R (version 
3.1.4) and a p-value of 0.05 was considered the threshold for statistical significance.  
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3 Results: 
3.1 Baseline characteristics: 
Forty-two participants provided complete multi-modal imaging datasets (PET/CTs at 0 and 
6 months, and MRIs at 0 and 24 months). Baseline characteristics of the study population 
are summarized in table 1. The mean age of the population was 62.5 years, and 12 (28.6%) 
were female. Thirty-five participants (83.3%) had a prior history of cardiovascular disease, 
14 (33.3%) were diabetic, 30 (71.4%) had a history of hypertension and 4 (9.5%) were 
smokers. Compared to individuals in dal-PLAQUE who did not provide complet multi-
modality data, participants included in this analysis had a lower mean body mass index 
(BMI) and systolic blood pressure. Also, the baseline FDG target-to-background ratio on 
PET, and baseline mean wall thickness (MWT) and mean wall area (MWA) on MRI were 
lower in included participants.   
3.2 Atherosclerosis progression in participants with or without increased arterial 
inflammation  
Eighteen participants (42.8%) manifested an increase in arterial inflammation measured 
by PET/CT between baseline and 6 months. Structural atherosclerosis progression 
measured by percent changes in MWT and MWA on MRI over 24 months are summarized 
in Table 2. In participants with an early increase in arterial inflammation (baseline to 6 
months), structural atherosclerosis progression was also seen at 2 years. Conversely, in 
participants with no increased arterial inflammation at 6 months, no significant 
atherosclerosis progression was observed. 
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In the univariate linear regression analysis, evidence of increased arterial 
inflammation at 6 months was associated with a significantly greater change in both MWT 
and MWA on MRI at 24 months (Table 3 and Figure 1a). In participants with increased 
arterial inflammation on PET over 6 months, the increase in MWT over 24 months was 
approximately 15.8% greater when compared to participants without increased arterial 
inflammation (p=0.038). Similarly, in participants with increased arterial inflammation at 6 
months, the increase in MWA at 24 months was approximately 21% greater 
(p=0.027)(Table 3 and Figure 1b). These differences remained significant after adjusting 
for age, gender and treatment allocation; and for additional clinical, biochemical or imaging 
variables significantly associated with changes in MWT on univariate analyses (see 
supplementary table 1). Results also remained significant after adjusting for structural 
atherosclerosis measurements obtained at 6-months (i.e mean wall area on MRI; p=0.04). 
On the other hand, baselineFDG uptake was not significantly associated with percent 
change in MWA over 24 months either on univariate analysis (β = -21.01 (SE 11.10), p = 
0.07) or after adjusting for demographic variables and treatment allocation (β = -22.9 (SE 
13.6), p = 0.10). Furthermore, using covariate adjustments specified in dalPLAQUE, we 
evaluated the effect of dalcetrapib on arterial inflammation (carotid atherosclerosis) 4. 
Compared to placebo, treatment with dalcetrapib did not significantly reduce carotid 
inflammation over 6 months (-5.1% [SE 4.1] change in TBR, p=0.22). It should be noted, 
however, that while the findings are consistent with the non-significant trend seen in the 
parent study, this sub-study analysis had limited power to assess the treatment effect.  
In sensitivity analyses, we evaluated the association between increased arterial 
inflammation at 6 months and absolute changes in MWT and MWA at 24 months. Results 
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are summarized in supplementary table 2, and were consistent with our primary 
observations. Both associations trended towards significance in univariate analyses, and 
were statistically significant after adjusting for other significant predictors (derived from 
the primary analysis). Finally, we observed that increased arterial inflammation was also 
associated with short-term atherosclerosis progression (also measured at 6-months) 
(Supplementary table 3).  
3.3 Changes in Inflammatory Biomarkers and Atherosclerosis Progression by MRI: 
Over 24 months, no significant positive associations between changes in inflammatory 
biomarkers and either changes in MWT or MWA observed (Supplementary Table 4). There 
was a small inverse association between changes in sVCAM (Vascular cell adhesion 
molecule) and both MWT and MWA. A trend towards a significant inverse association was 
also observed with changes in sICAM (Intercellular adhesion molecule) and both MWT and 
MWA. Changes in arterial inflammation measured by PET remained significantly associated 
with atherosclerosis progression after adjusting for changes in either sICAM (p=0.030) or 
sVCAM (p=0.022). Changes in arterial inflammation also remained significant after 
correcting for changes in CRP (p=0.047). 
3.4 Relationship between changes in arterial inflammation at 3 months and 
atherosclerosis progression at 24 months  
Three month PET studies were available in 41 participants. Changes in FDG uptake from 
baseline to 3 months correlated moderately with changes from baseline to 6 months 
(Pearson’s Correlation = 0.74, p <0.001). However, we did not observe any significant 
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associations between evidence of increased arterial inflammation at 3 months and percent 
change in either MWT (p-value = 0.19) or MWA (p-value = 0.16) at 24months.   
3.5 Mean Changes in Carotid Arterial Inflammation in Participants with the Highest 
Rates of Progression of Atherosclerosis on MRI 
In participants with the highest rate of atherosclerosis progression (defined as the highest 
tertile of change in MWT at 24 months), mean changes in TBR were significantly higher 
when compared to groups with evidence of less atherosclerosis progression (defined as the 
lower two tertiles)(0.09 [SD= 0.32] versus -0.16 [SD = 0.34], p=0.026, Figure 2a). Similar 
results were obtained when participants were grouped into tertiles based on changes in 
MWA (0.11 [SD = 0.28] for highest tertile versus -0.17 [SD=0.35] for lowest two tertiles, p = 
0.014, Figure 2b).   
3.6 Progression of atherosclerosis at 6 months compared to 24 months measured by 
MRI 
Thirteen of 35 participants (35.4%) had evidence of increasing wall thickness on MRI at 6 
months. Evidence of increasing MWT and 6-months was also associated with a greater rate 
of atherosclerosis progression at 24 months (see supplementary table 5). Change in MWT 
at 6 months as a continuous variable was highly correlated with change in MWT at 24-
months (Pearson’s correlation = 0.64, p <0.001). Results using MWA were consistent with 
those of MWT (see supplementary table 5). 
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4 Discussion: 
In this sub-study of dal-PLAQUE, we found that short-term changes in arterial 
inflammation predict long-term structural atherosclerosis progression. Participants with 
evidence of increased carotid inflammation measured by FDG-PET over 6-months had 
greater progression in carotid artery MWT and MWA on MRI at 2 years. Also, in those 
without evidence of increased arterial inflammation, no significant atherosclerosis 
progression was observed.  
These findings provide additional mechanistic insights into the consequences of 
arterial inflammation. Prior histologic, cross-sectional studies of carotid arterial imaging 
have shown that arterial inflammation measured by FDG-PET closely correlates with 
macrophage infiltration within the atheroma. 7, 11 Furthermore, carotid inflammation 
measured by FDG-PET has been shown to precede the development of calcification within 
the index artery measured by computed tomography.12 While these studies examining 
arterial inflammation cross-sectionally have increased our understanding of how arterial 
inflammation relates to both plaque activity and the progression of atherosclerosis, studies 
had yet to determine how changes in arterial inflammatory activity impact the progression 
of atherosclerosis. 
 Our study extends upon this current knowledge and provides two important 
pathophysiologic findings. First, changes in vascular inflammation observed over a short 
period appear to have both short and long-term consequences on atherosclerosis 
progression. Second, in those without evidence of increased inflammation, there were no 
significant changes in MWT or MWA observed, suggesting that atherosclerosis progression 
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can be substantially mitigated when inflammation is reduced. This is also supported by our 
observations that in participants with the highest rates of atherosclerosis progression on 
MRI, changes in arterial inflammation were significantly higher when compared to groups 
with evidence of less atherosclerosis progression. The critical threshold delineating those 
with or without increased inflammation may be of added importance, as we observed 
stronger associations when participants were dichotomized into these groups compared to 
examining arterial inflammation as a continuous measure (Supplementary appendix, 
section 1).  
Previous studies have shown that markers of systemic inflammation (e.g. CRP) also 
strongly predict plaque progression and cardiovascular events.13 Interestingly, in our 
exploratory analyses, we did not observe that changes in inflammatory biomarkers 
positively corresponded to atherosclerosis progression over the same period of time. These 
findings suggest that directly measuring inflammatory changes at the local, vascular level 
have a greater significance for identifying atherosclerosis progression compared to more 
general inflammatory biomarkers. However, whether this observation is generalizable to 
larger populations, and how this related to clinical outcomes, requires further study.    
We did not observe an association between baseline FDG arterial uptake on PET and 
subsequent atherosclerosis progression, a finding that conflicts with prior studies.12 
However, the current study included an intervention;  the arterial milue indeed changed 
over the course of this study,  as evidenced by the fact that a substantial percentage of 
individuals experienced changes in arterial inflammation. Thus comparisons between 
baseline arterial inflammatory measures and atherosclerosis progression should be 
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interpreted with caution, and should not suggest that cross-sectional PET measures of 
inflammation are not valuable. Indeed, in individuals who are not enrolled in interventional 
studies, the baseline arterial signal associates with both future plaque progression as well 
as future clinical events.12,14 Prior clinical outcome studies that have consistently 
demonstrated a strong association between baseline arterial inflammation and subsequent 
cardiovascular events. In 518 patients without a history of active cancer or CVD, we 
observed that baseline arterial FDG activity strongly predicted future adverse 
cardiovascular events at a mean follow up of 4.2 years, and provided additional predictive 
value above clinical factors.14 Similarly, in a study of 64 patients with significant 
symptomatic carotid stenosis that underwent PET imaging, Marnane et al. observed a 
significant association between carotid arterial inflammation and recurrent ipsilateral 
stroke.15 Our findings provide additional insight to these clinical observations, suggesting 
that altherosclerosis development is also partly related to the consequences of persistent 
inflammation.  
The results of our study further support the use of FDG-PET as a non-invasive 
imaging modality to predict the clinical impact of novel therapeutic agents on future 
cardiovascular outcomes. For example, using FDG-PET, a dose-dependent reduction in 
arterial inflammation has been observed over a 12-week period in response to the 
initiation of hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) 
therapy, which is similar to the dose-dependent reductions in cardiovascular outcomes 
observed in several large clinical trials.16-18 Conversely, in the overall dal-PLAQUE study, 
CETP modulation did not significantly impact changes arterial inflammation when 
compared to placebo within any of the predefined PET endpoints (though was nearly 
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significant in post-hoc analyses) . 4 Similarly, dalcetrapib did not reduce vascular events in 
clinical outcome trials.4, 19 Similarly, Inhibition of lipoprotein-associated phospholipase A2 
(Lp-PLA2), fails to reduce atherosclerotic inflammation,20 a finding that is consistent with 
the lack of clinical efficacy of Lp-PLA2 antagonists.20-22 Most recently, P38 MAP Kinase 
antagonists have been found to be ineffective in reducing any of the pre-defined PET 
endointsand have similarly been found to be ineffective in reducing clinical events. 23-25 
Thus for all classes of drugs for which there is PET imaging and clinical endpoint trials data, 
the pre-defined PET findings have been concordant with the clinical endpoint findings. 
Finally, we explored whether even earlier changes in FDG-PET uptake could predict 
atherosclerosis progression, and although we found 3-month changes in arterial 
inflammation correlated well with later, 6 month changes in the inflammatory signal, 3-
month changes themselves were not predictive of atherosclerosis progression. Ultimately, 
determining the optimal period for evaluate changes in arterial FDG uptake to determine 
the efficacy of novel therapeutic agents will depend on several factors, including the 
pharmacological properties of the treatments under investigation. 
As anticipated, we also observed that increasing WMT and WMA measured by MRI 
over 6 months was also associated with a higher rate of atherosclerosis progression over 
24 months. The consequences of these short-term structural changes to the arterial wall 
are complementary to our PET findings, and it is likely that these processes are 
interrelated, with biologically active atherosclerotic lesions also demonstrating early 
structural changes that both predict long-term atherosclerosis progression. Current 
cardiovascular pharmacologic therapies are widely given to patients with established CVD 
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or at high risk for CV events due to their low cost, and highly favorable benefit-to-risk 
profiles.26, 27 However, as future pharmacologic therapies develop, there may be a greater 
justification for measuring arterial inflammation with PET.20-22  Currently, anti-
inflammatory strategies for reducing CVD risk are being evaluated using both PET/CT 
imaging and clinical endpoint assessments (including colchicine, methotrexate  and 
interleukin-1 inhibition).28 If these are shown to concurrently improve arterial 
inflammation as well as clinical outcomes, such studies would provide additional data to 
support the hypothesis that targetting arterial inflammation per se is clinically beneficial; 
and move future Phase 1 studies of pharmacologic agents that target inflammation to Phase 
III clinical endpoint trials with greater confidence based on FDG-PET results. Also, it is 
possible that imaging arterial inflammation could be one day employed to identify which 
patients are most likely to benefit from novel anti-inflammatory drugs (particularly 
expensive drugs and/or those with substantial side-effects). In such a case, individuals with 
significant arterial inflammatory disease at baseline, and/or who have demonstrable 
improvements after treatment would be targeted to receive long-term treatment.  This 
personalized approach to CVD management would be similar to strategies currently used 
in oncology, where FDG-PET imaging is used for cancer staging , as well as post-induction 
re-staging of disease burden to guide further management decisions.29-31 However, prior to 
any clinical implementation, further studies are needed to determine whether the benefits 
of this approach would outweigh potential harms (e.g. radiation exposure), and whether it 
would be cost effective. 
The main strength of our paper is that all PET and MRI studies were performed in 
the context of a clinical trial, where imaging techniques were standardized across sites and 
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results were centrally interpreted. This significantly reduces the risk of biases related to 
variability in imaging procedures. Some limitations of our study also warrant 
consideration. Firstly, our primary outcome measures of MRI MWT and MWA represent 
non-invasive, surrogate markers of atherosclerosis development, since more invasive 
approaches were not employed in dal-PLAQUE. However, findings of atherosclerosis on 
MRI been shown to correlate well with observations of plaque burden by histology or other 
prognostic imaging modalities. For our analysis, serial PET and MRI images were available 
in approximately one-third of the participants randomised in dal-PLAQUE. Larger studies 
are needed to replicate these observations and demonstrate their generalizability in 
broader patient populations.   
In conclusion, our observations demonstrate that FDG-PET/CT can not only quantify 
the short lived atherosclerotic inflammatory process, but that identifying these changes are 
of value in predicting long term atherosclerosis progression. These findings support the 
current use of FDG-PET in drug efficacy assessment trials, and its potential use to direct 
future treatment strategies for targeting inflammatory pathways that inhibit 
atherosclerosis development. 
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 Table 1: Baseline Participant Characteristics: 
Characteristic:  Participants 
in Dal-Plaque 
(N=130) 
Participants 
in current 
study 
(N=42) 
Participants 
excluded 
from current 
study 
(N=88) 
p-value 
Clinical Characteristics 
    Age, years; Mean (SD) 63.6 (8.1) 62.5 (8.3) 64.2 (7.9) 0.27 
    Female, N(%) 24/130 
(0.18) 
12/42 (0.28) 12/88 (0.14) 0.07 
    Current smoker, N(%) 17/130 
(0.13) 
5/42 (0.12) 12/88 (0.14) 1.00 
    Treatment with active   
    study medication  
    (dalcetrapib) 
64/130 
(0.49) 
24/42 (0.57) 40/88 (0.46) 0.28 
    History of coronary heart  
    Disease, N(%) 
111/130 
(0.85) 
76/88 (0.86) 35/42 (0.83) 0.85 
    Diabetes, N(%) 39/130 
(0.30) 
14/42 (0.33) 25/88 (0.28) 0.71 
    Hypertension, N(%) 95/130 
(0.73) 
30/42 (0.71) 65/88 (0.74) 0.93 
    SBP, mmHg; mean (SD)  121.4 (15.4) 117.3 (14.3) 123.4 (15.6) 0.03 
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    LDL, mg/dL; mean (SD)   74.2 (21.0) 71.2 (20.1) 75.6 (21.4) 0.25 
    HDL, mg/dL; mean (SD)    44.4 (13.5) 46.9 (13.8) 43.2 (13.3) 0.15 
    BMI, kg/m2; mean (SD) 29.7 (5.5) 28.4 (4.3) 30.3 (6.0) 0.04 
    eGFR, ml/min/1.73 m2;     
    mean (SD) 
76.4 (12.9) 77.0 (11.7) 76.1 (13.5) 0.69 
Imaging Characteristics 
Magnetic resonance imaging: 
       Baseline mean carotid  
       wall thickness (mm) 
1.2(0.2) 1.1 (0.2) 1.2 (0.2) 0.02 
       Baseline mean carotid   
       wall area (mm2) 
28.8 (8.3) 26.3 (6.7) 30.6 (8.9) 0.01 
Positron Emission Tomography: 
     Baseline TBR of most  
     diseased segment of the  
     carotid artery 
2.0(0.5) 1.9 (0.4) 2.1 (0.5) 0.04 
 
BMI = body mass index, eGFR = estimated glomelular filtration rate, FDG= 18-
fluorodeoxyglucose, HDL = high density lipoprotein, LDL = low density lipoprotein, SBP = 
systolic blood pressure, SD = standard deviation  
 
  
 29 
Table 2: Changes in Atherosclerosis Progression over 24 Months in Participants With 
or Without Increased Arterial Inflammation at 6 Months 
Study Group 
Percent Change in MWT Percent Change in MWA 
mean 
(SE) 
P-value for 
within-
group 
change 
from 
baseline  
P-value 
between-
group 
comparison 
mean 
(SE) 
P-value 
for 
change 
from 
baseline  
P-value 
between-
group 
comparis
on 
All 
Participants 
8.49 
(3.80) 
0.013 NA 
12.98 
(4.98) 
0.031 NA 
Increased 
FDG uptake  
(N=18) 
17.49 
(7.19) 
0.026 
0.027 
25.50 
(9.77) 
0.018 
0.038 
No increased 
FDG uptake  
(N=24) 
1.74 
(3.42) 
0.616 
3.59  
(3.95) 
0.373 
FDG= 18-fluorodeoxyglucose. MRI = Magnetic Resonance Imaging. MWT = mean wall 
thickness. MWA = mean wall area. SE = standard error 
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Table 3. Atherosclerosis Progression in Participants with and without Increased 
Arterial Inflammation 
Endpoints Model Estimate (SE) Adjusted R2 of 
Model 
p-value 
Increased 
arterial 
inflammation 
at 6 months  
vs.  MWT at 
24 months  
Univariate Model 15.75 (7.36) 0.08 0.038 
Multivariable  
Model 1  
20.81 (8.10)    0.08 0.014 
Multivariable  
Model 2  
14.44 (5.86) 0.50 0.018 
Increased 
arterial 
inflammation 
at 6 months  
vs.  MWA at 
24 months 
Univariate Model 21.91 (9.58) 0.09 0.027 
Multivariable 
Model 1* 
25.81 (10.76) 0.06 0.022 
Multivariable 
Model 2*** 
22.80 (7.56) 0.52 0.004 
*Covariates: Age, gender, treatment allocation. **Covariates: PAI1 activity, baseline MWT 
on MRI. ***Covariates: PAI1A0, baseline MWA on MRI. Note: MWT and MWA were strongly 
correlated, therefore baseline MWT was used as a covariate in the analysis examining 
changes in MWT and baseline MWA was used in the analysis examining changes in MWA. 
BMI = body mass index, FDG = FDG= 18-fluorodeoxyglucose, MRI = Magnetic Resonance 
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Imaging, MWT = mean wall thickness, MWA = mean wall area, PAI1 = Plasminogen 
activator inhibitor-1, PET = positron emission tomography. 
Figure Legend: 
Figure 1: Percent Change in Carotid (A) Mean Wall Thickness and (B) Mean Wall Area at 24 
Months in Participants With or Without Evidence of Increased Arterial Inflammation at 6 
Months 
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Figure 2: Changes in Arterial Inflammation in Groups with the Greatest Amount of 
Atherosclerosis Progression Compared to Less Progression Measured by (A) Mean Wall 
Thickness and (B) Mean Wall Area 
 
 
